Skip to main content

Cefepime Uses, Side Effects, and More

 Cefepime

Brand name:- Kefage , ceficad, cepime0.5 , 1.0 g inj.

Cefepime is an antibiotic. It kills bacteria by preventing them from forming the bacterial protective covering (cell wall) which is needed for them to survive.

Pharmacodynamic:-

Cefepime is a fourth-generation cephalosporin antibiotic. It is active against Gram-negative bacteria such as Enterobacter spp., Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and Pseudomonas aeruginosa, and Gram-positive bacteria such as Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pneumoniae, Streptococcus pyogenes and Viridans group streptococci. Compared to third-generation cephalosporins, cefepime has an extended Gram-negative coverage. Whereas other cephalosporins are degraded by plasmid- and chromosome-mediated beta-lactamases, cefepime is stable and not significantly hydrolyzed by these enzymes. Cefepime is also a poor inducer of type 1 beta-lactamases and, therefore, a good alternative against bacteria resistant to third-generation cephalosporins.1

In animal models of infection, the time that the unbound plasma concentration of cefepime exceeds the minimum inhibitory concentration (MIC) of infecting organisms has been shown to correlate with treatment efficacy. It has been suggested that cefepime can cross the inflamed blood-brain barrier. This, along with its ability to inhibit γ-aminobutyric acid (GABA), could lead to the neurotoxic effects observed in some of the patients treated with cefepime.


 MECHANISM OF ACTION:-

Cefepime has a similar mechanism of action to other beta-lactams. Cefepime inhibits bacterial cell wall synthesis by covalently binding enzymes responsible for the final step in transpeptidation during peptidoglycan wall synthesis. This binding causes defects in the cell wall leading to autolysis and subsequent death of the organism. 

Cefepime has increased gram-negative coverage and is more stable against beta-lactamases when compared to third-generation cephalosporins due to a few mechanisms. One such mechanism is that penicillin-binding enzymes have a lower affinity for cefepime. Another is the chemical structure differs from older generations with a substitution of a side chain, lending it more activity against staphylococcal species. Cefepime is also a zwitterion giving it an advantage for faster cell wall penetration of gram-negative bacteria, which is why it has broader gram-negative coverage than the third-generation.

Cefepime, like most cephalosporins, is widely distributed throughout body tissue and fluids, including pleural fluid, synovial fluid, bones, cerebral spinal fluid, and breast milk. Cefepime rapidly metabolizes with less than 10% of the metabolized product undergoing excretion. The remaining compound gets excreted through glomerular filtration as an unchanged drug. The half-life is about 2 to 2.3 hours and is longer in patients with renal failure.

 Used:- 

Used to treat bacterial infections in many different parts of the body. It belongs to the class of medicines known as cephalosporin antibiotics. It works by killing bacteria or preventing their growth.

side effects:- 

Diarrhea, Increased white blood cell count (eosinophils), Injection site phlebitis, Skin rash, Increased liver enzymes, Positive Coombs test, Increased prothrombin time, Decreased phosphate level in blood, Increased partial thromboplastin time (PTT).

Dose:- 1-2 g i.v. 8-12 hourly. Child with febrile neutropenia 50mg/kg i.v. 8hourly. As directed by your doctor.

Comments

Popular posts from this blog

Cefpodoxime proxetil Uses, Side Effects, and More

 Cefpodoxime proxetil Brand name:- cefoprox ,cepodem,DOXCEF 100,200mg cap.  Cefpodoxime Proxetil is an antibiotic. It kills the bacteria by preventing them from forming the bacterial protective covering (cell wall) which is needed for them to survive. Pharmacodynamic:-  Cefpodoxime is shown to be effective against most Gram positive and Gram negative bacteria, except Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. Mechanism of action:-  Cefpodoxime is active against a wide spectrum of Gram-positive and Gram-negative bacteria. Cefpodoxime is stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and cephalosporins, due to their production of beta-lactamase, may be susceptible to cefpodoxime. Cefpodoxime is inactivated by certain extended spectrum beta-lactamases. The bactericidal activity of cefpodoxime results from its inhibition of cell wall synthesis. The active metabolite of cefpodoxime binds preferentially to penicilli

Cephalexin ( ZYD ) ( Cefalexin ) Uses, Side Effects, and More

 Cephalexin (ZYD) (Cefalexin) Brand name:-  Cephacillin 250,500mg cap; Sporidex, Alcephin,Cephaxin cap. Cephalexin (also called Cefalexin)  is the most common used orally effective first generation cephalosporin , similar in spectrum to cefazolin , but less active against penicillinase producing staphylococci and H. Influenza. Plasma protein binding is low; it attains High concentration in bile and is excreted unchanged in urine; t½ - 60min. Pharmacodynamic:-  Cephalexin (also called Cefalexin) is a first generation cephalosporin antibiotic. It is one of the most widely prescribed antibiotics, often used for the treatment of superficial infections that result as complications of minor wounds or lacerations.Label It is effective against most gram-positive bacteria through its inihibition of the cross linking reaction between N-acetyl muramicacid and N-acetylglucosamine in the cell wall, leading to cell lysis. Pharmacokinetics:- Cephalexin is rapidly and almost completely absorbed from t

BASILIXIMAB Uses, Side Effects, and More

 BASILIXIMAB BRAND NAME:- Simulect   BASILIXIMAB is another anti CD - 25 antibody with higher affinity for the IL-2 receptor, but shorter plasma t½ (1 week) . is a monoclonal antibody used to prevent rejection in kidney transplants. It is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used in combination with other medicines used to prevent organ rejection. PHARMACODYNAMIC:- Basiliximab functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.  MECHANISM OF ACTION:-  Basiliximab competes with IL-2 to bind to the alpha chain subunit of the IL2 receptor on the surface of the activated T lymphocytes and thus prevents the receptor from signaling. This prevents T cells from replicating and also from activating B cells, which are responsible for the production of antibodies, which would bind to the trans